CLINICAL STUDIES ON PATIENTS WITH KNOWN OR SUSPECTED PARASITIC DISEASES

这些研究的目的是增加对发病机制的了解。 对寄生虫病的诊断、治疗和改进 预防措施。除了在NIH的研究外，临床 已在流行性感冒流行地区开展了患者调查。 危地马拉(盘尾丝虫病)、印度和巴西(丝虫病)、扎伊尔和 牙买加(棘球线虫病)、洪都拉斯(囊虫病和利什曼病)和 巴拿马(利什曼病)。 这些研究清楚地定义了HTLV-1感染之间的联系 和弓形虫病，但似乎没有类似的关系 艾滋病毒感染。 实验室研究允许定义监管和 IgE、IgG4和嗜酸性粒细胞反应的致病机制 对蠕虫的感染，以及分子的鉴定 可能与贾第鞭毛虫病相关的抗原变异有关 班氏丝虫病、丝虫病和丝虫病的保护性免疫 棘球线虫病。 伊维菌素治疗班氏丝虫病的临床试验表明 有效和安全地清除微丝虫病，由于其 单剂量口服治疗模式，实用得多 在对照项目中，比旧的抗丝虫病药物二乙基卡马津更有效。

The goal of these studies is to increase understanding of the pathogenesis of parasitic diseases and to improve their diagnostic, therapeutic and preventative measures. In addition to studies at NIH, clinical investigation of patients has been carried out in the endemic areas of Guatemala (onchocerciasis), India and Brazil (filariasis), Zaire and Jamaica (strongyloidiasis) Honduras (cysticercosis and leishmaniasis) and Panama (leishmaniasis). Such studies have clearly defined an association between HTLV-1 infection and strongyloidiasis, but there seems to be no similar relationship with HIV infections. Laboratory studies have permitted definition of the regulatory and pathogenetic mechanisms underlying the IgE, IgG4, and eosinophil responses to helminth infection, as well as the identification of molecules responsible for antigenic variation in giardiasis likely involved in protective immunity in bancroftian filariasis, onchocerciasis and strongyloidiasis. Therapeutic trials of ivermectin for bancroftian filariasis have shown it to be effective and safe in clearing microfilaremia and, because of its single-oral-dose mode of therapy, to be considerably more practical for use in control programs than the older antifilarial drug, diethylcarbamazine.